|
Theravance Biopharma inc (NASDAQ: TBPH) |
|
Theravance Biopharma inc
TBPH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Theravance Biopharma Inc growth rates, revenue grew
by 22.69 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1256
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Theravance Biopharma Inc net loss decreased from $-16 millions, to $-13 millions in III. Quarter 2024,
• More on TBPH's Growth
|
|
Theravance Biopharma Inc realized a net loss in trailing twelve months.
Theravance Biopharma Inc realized cash reduction of $ -1.02 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 7.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.5.
• More on TBPH's Valuation
|
|
|
|
|
Theravance Biopharma Inc realized net loss in trailing twelve months.
Theravance Biopharma Inc realized cash outflow of $ -1.02per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 7.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.5.
Theravance Biopharma Inc Price to Book Ratio is at 2.5 lower than Industry Avg. of 82.97. and higher than S&P 500 Avg. of 0.02
• More on TBPH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com